Skip to main content
SpringerLink
Log in

Pramipexole Extended Release

In Parkinson’s Disease

  • Adis Drug Profile
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Pramipexole extended release (ER) is a non-ergolinic dopamine receptor agonist available for use as a once-daily oral treatment for the signs and symptoms of early and advanced idiopathic Parkinson’s disease.

Once-daily pramipexole ER and three times-daily pramipexole immediate release (IR) have similar exposure over 24 hours. The ER formulation is associated with fewer fluctuations in plasma pramipexole concentrations over this period.

Pramipexole ER improved the symptoms of Parkinson’s disease in three well designed trials in adults with early or advanced disease, as measured by changes from baseline in the sum of the Unified Parkinson’s Disease Rating Scale (UPDRS) parts II and III subtotal scores.

In a 9-week study, the majority of patients with early Parkinson’s disease who were receiving stable pramipexole IR treatment were successfully switched to pramipexole ER.

Relative to placebo at week 18, pramipexole ER 0.375–4.5 mg (of the salt) once daily significantly decreased the sum of the UPDRS parts II and III subtotal scores from baseline in two trials in patients with early or advanced Parkinson’s disease, and also reduced the percentage of off-time during waking hours in patients with advanced disease. The efficacy of pramipexole ER was maintained after 33 weeks of treatment in the trials in patients with early or advanced Parkinson’s disease.

Pramipexole ER was generally well tolerated in patients with Parkinson’s disease, with the rate of adverse events being generally similar to that with pramipexole IR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. de Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol 2006 Jun; 5(6): 525–35

    Article  PubMed  Google Scholar 

  2. von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 2005 Apr; 15(4): 473–90

    Article  Google Scholar 

  3. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron 2003 Sep 11; 39(6): 889–909

    Article  PubMed  CAS  Google Scholar 

  4. National Institute for Health and Clinical Excellence. Parkinson’s disease: diagnosis and management in primary and secondary care (NICE clinical guideline 35) [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/cg035niceguideline.pdf [Accessed 2010 Jan 15]

  5. European Medicines Agency. Pramipexole (Mirapexin® prolonged-release tablets): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Mirapexin/emea-combined-h134en.pdf [Accessed 2010 Feb 3]

  6. European Medicines Agency. Pramipexole (Sifrol® prolonged-release tablets): summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/Sifrol/emea-combined-h133en.pdf [Accessed 2010 Feb 3]

  7. Boehringer Ingelheim. Boehringer Ingelheim receives approval from the European Commission for Mirapexin®/ Sifrol® prolonged-release, once daily tablet for the treatment of Parkinson’s disease [media release]. 2009 Oct 14

  8. Grosset D, Antonini A, Canesi M, et al. Adherence to anti-parkinson medication in a multicentre European study. Mov Disord 2009 Apr 30; 24(6): 826–32

    Article  PubMed  Google Scholar 

  9. Dooley M, Markham A. Pramipexole: a review of its use in the management of early and advanced Parkinson’s disease. Drugs Aging 1998 Jun; 12(6): 495–514

    Article  PubMed  CAS  Google Scholar 

  10. Haertter S, Koenen-Bergmann M, Narjes H, et al. A single dose five-way cross-over study to establish an in vitro/in vivo correlation (IVIVC) for oral extended release (ER) formulations with 0.375mg pramipexole [abstract no. P1244]. Presented at the 12th Congress of the European Federation of Neurological Societies; 2008 Aug 23–26; Madrid

  11. Dansirikul C, Ander Riss B, Hauser RA, et al. Population-pharmacokinetic analysis of pramipexole extended-release in patients with Parkinson’s disease [abstract no. P06.147]. Neurology 2009; 72(11 Suppl. 3): A318

    Google Scholar 

  12. Koenen-Bergmann M, Haertter S, Schepers C. A multiple rising-dose bioequivalence phase I study with a pramipexole extended release (ER) formulation [abstract no. P1248]. Presented at the 12th Congress of the European Federation of Neurological Societies; 2008 Aug 23–26; Madrid

  13. Schapira AHV. Etiology of Parkinson’s disease. Neurology 2006 May 23; 66(10 Suppl. 4): S10–23

    Article  PubMed  Google Scholar 

  14. Mierau J, Schneider FJ, Ensinger HA, et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 1995 Jun 23; 290(1): 29–36

    Article  PubMed  CAS  Google Scholar 

  15. Piercey MF, Hoffmann WE, Smith MW, et al. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 1996 Sep 19; 312(1): 35–44

    Article  PubMed  CAS  Google Scholar 

  16. Mierau J, Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol 1992 May 14; 215(2–3): 161–70

    Article  PubMed  CAS  Google Scholar 

  17. Albrecht S, Buerger E. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole. Curr Med Res Opin 2009 Dec; 25(12): 2977–87

    Article  PubMed  CAS  Google Scholar 

  18. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002 Apr 3; 287(13): 1653–61

    Article  Google Scholar 

  19. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009 May; 66(5): 563–70

    Article  Google Scholar 

  20. Samuels ER, Hou RH, Langley RW, et al. Comparison of pramipexole with and without domperidone co-administration on alertness, autonomic, and endocrine functions in healthy volunteers. Br J Clin Pharmacol 2007; 64(5): 591–602

    Article  PubMed  CAS  Google Scholar 

  21. Rascol O, Barone P, Debieuvre C, et al. Easy switching from immediate- to extended-release pramipexole in early Parkinson’s disease at the same daily dosage [abstract no. Th-255]. Mov Disord 2009; 24Suppl. 1: S362. Plus poster presented at the 13th Annual International Congress of Parkinson’s Disease and Movement Disorders; 2009 Jun 7–11; Paris

    Google Scholar 

  22. Poewe W, Barone P, Hauser RA, et al. Pramipexole extended-release is effective in early Parkinson’s disease [abstract no. We-185]. Mov Disord 2009; 24Suppl. 1: S273. Plus poster presented at the 13th Annual International Congress of Parkinson’s Disease and Movement Disorders; 2009 Jun 7–11; Paris

    Google Scholar 

  23. Schapira A, Barone P, Hauser RA, et al. Efficacy and safety of pramipexole extended-release for advanced Parkinson’s disease [abstract no. We-199]. Mov Disord 2009; 24Suppl. 1: S277–8. Plus poster presented at the 13th Annual International Congress of Parkinson’s Disease and Movement Disorders; 2009 Jun 7–11; Paris

    Google Scholar 

  24. Hauser R, Salin L, Koester J. Double-blind evaluation of pramipexole extended-release (ER) in early Parkinson’s disease [abstract no. S43.003]. Neurology 2009 Mar 17; 72(11 Suppl. 3): A412

    Google Scholar 

  25. Rascol O, Barone P, Debieuvre CD, et al. Overnight switching from immediate- to extended-release pramipexole in early Parkinson’s disease [abstract no. P06.152]. Neurology 2009 Mar 17; 72(11 Suppl. 3): A 320. Plus poster presented at the 61st American Academy of Neurology Annual Meeting; 2009 Apr 25–May 2; Seattle (WA)

    Google Scholar 

Download references

Acknowledgements and Disclosures

The manuscript was reviewed by: D. Nyholm, Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden; C.H. Waters, Department of Neurology, University of Southern California, Los Angeles, California, USA.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was also offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    Claudine M. Chwieduk & Monique P. Curran

Authors
  1. Claudine M. Chwieduk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monique P. Curran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudine M. Chwieduk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chwieduk, C.M., Curran, M.P. Pramipexole Extended Release. CNS Drugs 24, 327–336 (2010). https://doi.org/10.2165/11204570-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11204570-000000000-00000

Keywords

Search

Navigation